Digoxin therapy: A persisting interest despite contrary winds.

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Digoxin has been a cornerstone in heart failure treatment for over two centuries.
• Concerns regarding adverse effects and lack of mortality benefit in the DIG study diminished its clinical standing, particularly in elderly patients with renal impairment.
• The perception of digoxin as an outdated medication is exacerbated by limited pharmaceutical promotion due to its low cost and generic availability.

Purpose of the Study:

• To re-evaluate the role of digoxin in the management of chronic heart failure.
• To challenge the prevailing negative perception of digoxin by examining existing literature.
• To advocate for a balanced consideration of digoxin as a potential first-line therapy alongside ACE inhibitors and beta-blockers.

Main Methods:

• Literature review of studies on digoxin in heart failure.
• Analysis of data regarding digoxin's effects on morbidity and mortality.
• Cost-effectiveness analysis of digoxin therapy.

Main Results:

• Evidence suggests digoxin can reduce morbidity and mortality when maintained at low serum concentrations (<1.0 ng/ml).
• Digoxin exhibits a favorable cost-effectiveness ratio compared to other heart failure therapies.
• Despite historical concerns, specific patient populations may still benefit from digoxin therapy.

Conclusions:

• The negative perception of digoxin in chronic heart failure may be disproportionate to its demonstrated benefits, particularly regarding morbidity reduction and cost-effectiveness.
• Low-dose digoxin therapy (<1.0 ng/ml) remains a viable option with positive clinical outcomes and economic advantages.
• A reassessment of digoxin's place in heart failure treatment guidelines, considering its benefits at low serum concentrations, is warranted.